
OmniAb, Inc.
NASDAQ•OABI
CEO: Mr. Matthew W. Foehr
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-09-30
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Contact Information
Market Cap
$210.94M
P/E (TTM)
-3.5
37
Dividend Yield
--
52W High
$4.02
52W Low
$1.22
52W Range
Rank46Top 59.5%
3.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q3 2025 Data
Revenue
$2.24M-46.33%
4-Quarter Trend
EPS
-$0.14-12.50%
4-Quarter Trend
FCF
-$9.95M+47.77%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Operating Expenses Decline Total costs $63.5M, down 14% for nine months, reflecting lower R&D and G&A expenses compared to prior year.
Platform Adoption Growth Active partners reached 104, supporting 399 active programs as of September 30, 2025, indicating platform usage expansion.
Successful Equity Financing Financing activities provided $28.0M cash, driven by the August 2025 PIPE raising approximately $30.0M gross proceeds.
Cash Runway Secured Cash, equivalents, and investments total $59.5M, sufficient to support operations for at least the next 12 months.
Risk Factors
Revenue Milestone Dependency Nine-month total revenue fell 34% to $10.3M due to timing of license agreements and milestone achievement fluctuations.
Increased Net Loss Nine-month net loss widened to $(50.6M) versus $(49.0M) last year, driven by lower revenue recognition timing.
Healthcare Regulatory Headwinds New legislation like the One Big Beautiful Bill Act may reduce Medicaid funding, potentially impacting partner sales profitability.
Warrants Out of Money Warrants remain 'out of the money' as stock price is below $11.50 exercise price, delaying potential cash inflow.
Outlook
Focus on Royalty Value Long-term value driven by royalties based on global sales of future partner programs, expected to be recurring payments.
R&D Investment Continuation Expect to incur losses while investing in R&D to improve platform, market technologies, and expand operational systems.
Future Capital Needs Liquidity requirements may necessitate raising additional capital via equity or debt if anticipated cash flows prove insufficient.
Unrecognized Compensation Expense Unrecognized stock compensation expense of $17.7M for options expected to be recognized over the next 1.19 years.
Peer Comparison
Revenue (TTM)
$52.93M
IVVD$50.04M
SGMO$32.88M
Gross Margin (Latest Quarter)
SGMO100.0%
94.3%
IVVD91.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IVVD | $280.06M | -6.0 | -93.0% | 1.9% |
| TARA | $238.87M | -4.9 | -35.1% | 2.5% |
| OBIO | $228.12M | -2.1 | -320.1% | 1.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-40.8%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 17, 2026
EPS:-$0.08
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $2.24M-46.3%|EPS: $-0.14-12.5%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $3.90M-48.8%|EPS: $-0.15+15.4%MeetForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 8, 2025|Revenue: $4.15M+9.3%|EPS: $-0.17-10.5%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 18, 2025|Revenue: $26.39M-22.8%|EPS: $-0.61-19.6%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $4.17M-23.8%|EPS: $-0.16+0.0%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 8, 2024|Revenue: $7.61M+9.6%|EPS: $-0.13-13.3%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 9, 2024|Revenue: $3.80M-77.5%|EPS: $-0.19+208.9%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 25, 2024|Revenue: $34.16M-42.2%|EPS: $-0.51-96.2%Miss